Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety

Philippe Bouchard, Bouchard P, Nathalie Chabbert‐Buffet, Chabbert-Buffet N, Nathalie Chabbert-Buffet, Fauser BC, Bart C J M Fauser
Fertility and sterility · 2011 · vol. 96(5) , pp. 1175–1189 · doi:10.1016/j.fertnstert.2011.08.021 · PMID:21944187 · W2171626715
article OA: bronze CC0 ⤵ 31 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This review examines the pharmacology, clinical efficacy, and safety of selective progesterone receptor modulators (SPRMs) for applications in reproductive medicine.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo discuss the mechanism of action of selective progesterone receptor modulators (SPRMs) and summarize the preclinical and clinical efficacy and safety data supporting the potential use of these compounds for gynecologic indications.DesignRelevant publications from 2005 onward were identified using a PubMed search. Additional relevant articles were identified from citations within these publications.SettingNone.Patient(s)None.Intervention(s)None.Main outcome measure(s)None.Result(s)Mifepristone was first developed as a progesterone receptor antagonist and licensed for pregnancy termination because of the unique property of this compound to terminate pregnancy when associated with prostaglandins. Then SPRMs were developed, and among those ulipristal acetate, an efficient emergency contraceptive. Because SPRMs effectively inhibit endometrial proliferation and reduce endometriotic lesions in animal models, this suggests a possible role in the treatment of endometriosis in humans. Finally, a number of double-blind, randomized, placebo-controlled trials have demonstrated the efficacy of asoprisnil, mifepristone, telapristone acetate, and ulipristal acetate in reducing leiomyoma and uterine volume, and suppressing bleeding in women with uterine fibroids.Conclusion(s)Mifepristone in combination with prostaglandins has been licensed for pregnancy termination because of its unique ability is this area. Ulipristal acetate is available for emergency contraception. Several SPRMs hold further promise as an effective medical therapy for patients suffering from endometriosis and leiomyoma.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Hormone Antagonists Receptors, Progesterone Reproduction Abortifacient Agents Abortifacient Agents Abortion, Induced Animals Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Contraception, Postcoital Contraceptives, Postcoital Contraceptives, Postcoital Endometriosis Endometriosis Endometriosis Evidence-Based Medicine Female Hormone Antagonists Hormone Antagonists Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (31)

Source provenance

europepmc
last seen: 2026-07-26T06:08:39.051465+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:16:29.858026+00:00
License: CC0 · commercial use OK